(Q57771987)

Expert Opinion on Investigational Drugs

inferred from title

author

Kamyar Kalantar-Zadeh

object named as

Kamyar Kalantar-Zadeh

series ordinal

2

0 references

Csaba P. Kovesdy

series ordinal

1

object named as

Csaba P Kovesdy

0 references

language of work or name

English

0 references

publication date

April 2008

0 references

published in

0 references

volume

17

0 references

issue

4

0 references

page(s)

451-67

0 references

cites work

Effect of dialysis dose and membrane flux in maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Homocysteine in uraemia--a puzzling and conflicting story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Inflammatory and atherosclerotic interactions in the depleted uremic patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

C-reactive protein and chronic Chlamydia pneumoniae infection--long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Acute-phase inflammatory response to periodontal disease in the US population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The role of tumor necrosis factor in the pathophysiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Endotoxin and immune activation in chronic heart failure: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Associations between circulating inflammatory markers and residual renal function in CRF patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Cytokines and bioincompatibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Tumor necrosis factor blockade: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

IMiDs: a novel class of immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Oxpentifylline inhibits tumor necrosis factor‐α mRNA transcription and protects against arthritis in mercuric chloride‐treated Brown Norway rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

An open study of oxpentifylline in early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment o

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Interleukin-1 receptor antagonist

21 January 2018

2 references

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

21 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist

2 November 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Pharmacokinetics of anakinra in subjects with different levels of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Cytokine traps: multi-component, high-affinity blockers of cytokine action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Interleukin 6 and its receptor: ten years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

New therapies for treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Immune regulation by CD40 and its ligand GP39.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The role of T-cell costimulatory activation pathways in transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

New therapies for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

New approaches to the treatment of dense deposit disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

A proinflammatory role for IL-18 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Interleukin-18 and the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Function and activation of NF-kappa B in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Evidence for a potent antiinflammatory effect of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Prostaglandins, aspirin-like drugs and the oedema of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Locking a leukocyte integrin with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Study of Heart and Renal Protection (SHARP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Why do we need a statin trial in hemodialysis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Malnutrition in hemodialysis patients: what therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Does megestrol acetate down-regulate interleukin-6 in patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The effects of megestrol acetate on nutritional parameters in a dialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Interactions of oxidants with vascular signaling systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Chronic kidney disease: the global challenge

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

The Environment and Disease: Association or Causation?

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Oxidants and antioxidants in atherogenesis. An appraisal

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Heparin in inflammation: potential therapeutic applications beyond anticoagulation.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways

2 November 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

2 November 2018

https://api.crossref.org/works/10.1517%2F13543784.17.4.451

Biologic basis for interleukin-1 in disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

NF-kappa B and Rel: participants in a multiform transcriptional regulatory system.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Interleukin-6 in biology and medicine

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5500838

Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure

2 November 2018

1 reference

12 December 2020

Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis

1 reference

12 December 2020

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

1 reference

12 December 2020

[Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis]

1 reference

12 December 2020

Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study

1 reference

12 December 2020

High-dose statins in acute coronary syndromes: not just lipid levels

1 reference

12 December 2020

Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain

1 reference

12 December 2020

The effects of moderate doses of megestrol acetate on nutritional status and body composition in a hemodialysis patient

1 reference

12 December 2020

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment

1 reference

12 December 2020

The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis

1 reference

12 December 2020

Plasma C-reactive protein is linked to backfiltration associated interleukin-6 production

1 reference

12 December 2020

Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports

1 reference

12 December 2020

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

12 December 2020

Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial

1 reference

12 December 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

12 December 2020

Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects

1 reference

12 December 2020

Statins as a newly recognized type of immunomodulator

1 reference

12 December 2020

C-reactive protein is a strong predictor of mortality in hemodialysis patients

1 reference

12 December 2020

Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes

1 reference

12 December 2020

Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure

1 reference

12 December 2020

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

1 reference

12 December 2020

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

12 December 2020

IkappaB-NF-kappaB structures: at the interface of inflammation control

1 reference

12 December 2020

Rheumatoid arthritis and heparin

1 reference

12 December 2020

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

12 December 2020

Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1–stimulated cartilage erosion and chondrocyte responsiveness

1 reference

12 December 2020

Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?

1 reference

12 December 2020

Short bacterial DNA fragments: detection in dialysate and induction of cytokines

1 reference

12 December 2020

Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification?

1 reference

12 December 2020

Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms

1 reference

12 December 2020